Mon–Thu 8am–4:30pm CT · Fri 8am–3pm CT
Clinical Trial · NCT02952469
Overview
The purpose of this Radioactive Drug Research Committee (RDRC) study is to collect initial data regarding biodistribution, reproducibility, and dosimetry for the radiotracer Ga-68 PSMA-HBED-CC, an agent which may be useful for the early detection of metastatic prostate cancer. Investigators will use a test and re-test design in all patients to determine reproducibility of lesion detection and signal intensity, and will include dynamic imaging in some patients for the purposes of dosimetry. Patients with known metastatic prostate cancer will be recruited and imaged on two occasions within the course of 15 days.
Sponsor
University of Iowa
Phase
Early Phase 1
Contacts
Janet Pollard, M.D. (PRINCIPAL_INVESTIGATOR)
ClinicalTrials.gov
NCT02952469Drug / Compound
Help us improve your experience